News & numbers Research and development


Deloitte’s 2022 Global Life Sciences Outlook report gives us a snippet of R&D behaviour over the past few years, including insight into decentralised clinical trials, which have become more commonplace since the start of the Covid-19 pandemic.


A recent study from the Tufts Center for the Study of Drug Development compared published benchmarks on trial cycle times and costs with data from more than 150 decentralised trials conducted by software firm Medable.


The findings:


On average, decentralised clinical trials (DCTs) are associated with reduced clinical trial timelines, recruitment, and higher retention rates.


For example, decentralised phase 2 studies were completed one to three months faster than traditional trials, a net benefit up to five times greater than the investment required; phase 3 was 14 times greater.


998


Not yet recruiting


Total number of clinical trials related to Covid-19 vaccines and treatments as of January 17, 2022 199


Enrolling by invitation


2,908 Recruiting


743


Active, not recruiting


7,299 total


Covid-19 trials (as of 17 Jan 2022)


1,990 Completed


461 Other


Source: NIH Clinical Trials


Deloitte has been tracking return on pharmaceutical innovation since 2010. Up until 2020, companies tracked experienced a decade-long decline in R&D productivity. But in 2021, analysis of 15 large pharmaceutical companies shows a significant uptick for the cohort’s internal rate of return (IRR)—7%, up from 2.7% in 2020.


Pharma companies’ total R&D spend in 2020 Company


1 Merck


2 Roche Pharmaceuticals (division of Roche Group)


3 Bristol Myers Squibb


4 Janssen (Johnson & Johnson’s pharmaceutical segment)


5 Pfizer 6 Novartis 7 AbbVie 8 GlaxoSmithKline 9 Sanofi 10 Eli Lilly 11 AstraZeneca 12 Gilead Sciences 13 Takeda Pharmaceutical 14 Amgen 15 Biogen


Source: Drug & Discovery 2021


USD for 2020 $13,558,000,000


$12,164,234,743 $11,143,000,000 $9,563,000,000 $9,405,000,000 $8,980,000,000 $6,557,000,000 $6,509,126,400 $6,303,060,000 $6,086,000,000 $5,991,000,000 $5,039,000,000 $4,611,350,440 $4,207,000,000 $3,990,900,000


R&D returns have seen a large uptick in 2021 IRR is the highest it has been since 2014 Source: Nurturing growth, Measuring the return from, pharmaceutical innovation 2021, Deloitte Centre for Health Solutions UK, January 2022.


Uptick in R&D returns for biopharma cohort for 2021 (15 biopharma companies were analysed by Deloitte)


8 6 4 2 0


2013 2014 2015 2016 2017 2018 2019 2020 2021


Covid-19 may have taken a bit of a backseat lately, but data from NIH Clinical Trials shows that thousands of vaccines and treatments are being trialled to combat the disease.


Source: Deloitte’s 2022 Global Life Sciences Outlook: Digitalization at scale: Delivering on the promise of science Clinical Trials Insight / www.worldpharmaceuticals.net 7


Kit8.net; pancha.me/Shutterstock.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53